TOBIN HealthOSChronic-disease intelligence

TOBIN Intelligence Library · evidence review

PCOS & Hormonal Dysregulation

PCOS is approached as a metabolic–endocrine phenotype: androgen and insulin signaling, adipose inflammation, nutrient status and endocrine-active exposures are evaluated side by side.

PCOS & Hormonal Dysregulation on TOBINintel.org →

What is well established

2 links
  • Hyperinsulinemia → Ovarian androgen productionA

    Insulin amplifies LH-driven theca-cell androgen synthesis and lowers SHBG.

    Established causal · Multiple high-quality guidelines or meta-analyses

  • Inositol and vitamin D insufficiency → Ovulatory dysfunctionC

    Small trials report improved ovulatory frequency with myo-inositol; effect sizes vary.

    Randomized evidence · Preliminary human evidence

What is suspected, not proven

2 links
  • Adipose inflammation → Insulin resistanceB

    Cytokine signaling contributes to peripheral insulin resistance in PCOS cohorts.

    Open question: the association may reflect confounding or reverse causation; intervention trials would settle it.

  • Endocrine-active exposure (e.g. bisphenols) → Androgen and SHBG alterationC

    Cross-sectional studies report higher urinary bisphenol levels in PCOS; direction of effect is unresolved.

    Open question: the association may reflect confounding or reverse causation; intervention trials would settle it.

iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.

Domain emphasis

B Hormonal Balance · 1T Toxins · 0.8O Oxidative Stress · 0.7I Inflammation & Infection · 0.7N Nutrition · 0.7

Gut bacteriome and bile-acid patterns are tracked as potential modifiers of androgen metabolism, framed explicitly as a hypothesis.

Related Quadpandemics

  • I · Estrogen & Endocrine Disruption

    Endocrine-active chemicals are widely measurable in the population; their health effects must be evaluated exposure by exposure.

  • II · Obesity & Metabolic Dysfunction

    Obesity is a signaling and exposure problem, not a number on a scale.

  • III · Allergy & Immune Dysregulation

    Allergic and immune-complex disease is the fastest-rising chronic burden of the century.

  • IV · Anxiety, Depression & Neurobehavioral Health

    Mood symptoms are assessed responsibly — never automatically attributed to toxins or hormones.

Labs that inform this review

  • Fasting insulin (2.0–8.0 µIU/mL) — Insulin signaling load; pairs with glucose for HOMA-IR. Marked elevation with symptoms warrants clinician review.
  • ApoB (< 90 (lower if high risk) mg/dL) — Atherogenic particle count; better risk discrimination than LDL-C alone. Persistently high values deserve a cardiovascular risk discussion.
  • TSH (0.4–4.0 mIU/L) — First-line thyroid signaling test. Any abnormal result should be confirmed and reviewed clinically.
  • Estradiol (Cycle- and sex-dependent pg/mL) — Central to Pandemic I assessment, interpreted with cycle timing. Interpretation requires a clinician who knows your cycle and medication context.
  • Free T4 (0.8–1.8 ng/dL) — Circulating thyroid hormone; confirms whether an abnormal TSH reflects true thyroid under- or over-function. Low free T4 with symptoms, or any high value with palpitations, needs clinician review promptly.
  • Free T3 (2.3–4.2 pg/mL) — Active thyroid hormone, formed mostly by conversion of T4 in tissues. High free T3 with low TSH suggests hyperthyroidism — see a clinician.
  • Reverse T3 (9–24 ng/dL) — Inactive T4 metabolite that rises in stress, illness and calorie restriction. Do not change thyroid medication on rT3 alone; discuss with a clinician.

Score cutoffs used

  • HbA1c ADA Standards of Care: 5.7–6.4% prediabetes, ≥6.5% diabetes range
  • Fasting insulin Common functional reference; interpret only with a true fasting sample
  • ALT ACG: upper limit of normal ≈ 29–33 U/L (men), 19–25 (women)
  • GGT Typical laboratory upper limit ≈ 50 U/L
  • TSH ATA/Endocrine Society: 0.4–4.5 mIU/L; >10 overt range
  • Blood lead CDC blood lead reference value 3.5 µg/dL (2021)
  • Blood mercury EPA reference dose ≈ 5.8 µg/L blood equivalent
  • Free T4 Typical reference 0.8–1.8 ng/dL (assay-specific); interpret with TSH (ATA)
  • Free T3 Typical reference 2.3–4.2 pg/mL; low T3 also occurs in illness and calorie restriction
  • Reverse T3 Typical reference 9–24 ng/dL; guidelines (ATA) do not recommend rT3 for routine diagnosis — grade D
  • Anti-TPO antibodies Common cutoff >34–35 IU/mL (assay-specific); marks Hashimoto's risk (ATA)
  • Thyroglobulin antibodies Common cutoff ≤4 IU/mL (Roche) — assay-specific; positive in ~60–80% of Hashimoto's
  • Small LDL-P NMR LipoProfile: ≤527 nmol/L reference
  • LDL particle size NMR: >20.5 nm pattern A, ≤20.5 pattern B
  • sdLDL-C (small dense LDL) Denka assay (Quest Cardio IQ, Boston Heart): <30 mg/dL optimal (lab-specific)

Key formulas and thresholds

Published clinical cutoffs
  • HOMA-IR = fasting glucose (mg/dL) × fasting insulin (µIU/mL) ÷ 405 — above 2.5 suggests insulin resistance (Matthews 1985).
  • BMI = weight (kg) ÷ height (m)² — 25–29.9 overweight, 30 or more obesity (WHO); lower cutoffs (23/27.5) for many Asian populations.
  • Waist-to-height ratio = waist ÷ height — 0.5 or more signals central adiposity (NICE 2022).
  • TG/HDL ratio = triglycerides ÷ HDL (mg/dL) — above 3 is associated with insulin resistance (observational).
  • HbA1c (%): concern above 5.6, scored 100 at 8 — ADA Standards of Care: 5.7–6.4% prediabetes, ≥6.5% diabetes range
  • Fasting insulin (µIU/mL): concern above 8, scored 100 at 40 — Common functional reference; interpret only with a true fasting sample
  • ALT (U/L): concern above 33, scored 100 at 200 — ACG: upper limit of normal ≈ 29–33 U/L (men), 19–25 (women)
  • GGT (U/L): concern above 50, scored 100 at 200 — Typical laboratory upper limit ≈ 50 U/L
  • TSH (mIU/L): concern above 4.5, scored 100 at 20; concern below 0.4, scored 100 at 0.01 — ATA/Endocrine Society: 0.4–4.5 mIU/L; >10 overt range
  • Blood lead (µg/dL): concern above 1, scored 100 at 10 — CDC blood lead reference value 3.5 µg/dL (2021)
  • Blood mercury (µg/L): concern above 5, scored 100 at 20 — EPA reference dose ≈ 5.8 µg/L blood equivalent
  • Free T4 (ng/dL): concern below 0.9, scored 100 at 0.5; concern above 1.8, scored 100 at 3.5 — Typical reference 0.8–1.8 ng/dL (assay-specific); interpret with TSH (ATA)
  • Free T3 (pg/mL): concern below 2.5, scored 100 at 1.8; concern above 4.4, scored 100 at 7 — Typical reference 2.3–4.2 pg/mL; low T3 also occurs in illness and calorie restriction
  • Reverse T3 (ng/dL): concern above 24, scored 100 at 40 — Typical reference 9–24 ng/dL; guidelines (ATA) do not recommend rT3 for routine diagnosis — grade D
  • Anti-TPO antibodies (IU/mL): concern above 34, scored 100 at 500 — Common cutoff >34–35 IU/mL (assay-specific); marks Hashimoto's risk (ATA)
  • Thyroglobulin antibodies (IU/mL): concern above 4, scored 100 at 200 — Common cutoff ≤4 IU/mL (Roche) — assay-specific; positive in ~60–80% of Hashimoto's
  • Small LDL-P (nmol/L): concern above 527, scored 100 at 1000 — NMR LipoProfile: ≤527 nmol/L reference
  • LDL particle size (nm): concern below 20.5, scored 100 at 19.5 — NMR: >20.5 nm pattern A, ≤20.5 pattern B
  • sdLDL-C (small dense LDL) (mg/dL): concern above 30, scored 100 at 60 — Denka assay (Quest Cardio IQ, Boston Heart): <30 mg/dL optimal (lab-specific)

iThese thresholds organize where to look; they do not diagnose. Laboratory ranges, age, sex and pregnancy change interpretation.

Published sources

Guidelines and landmark studies
Protocols for PCOS & Hormonal DysregulationCalculate my TOBIN scoresAll reviews